News Room

[BACK TO ARTICLES]

Adcock Ingram wins approximately R2 billion of the State’s three-year Anti-Retroviral Tender

2019-02-18 02:01:35 PM

15 February 2019

Adcock Ingram wins approximately R2 billion of the State’s three-year Anti-Retroviral Tender

Johannesburg – Following the announcement by the South African National Treasury Department regarding the results of the South African Government’s National Anti-Retroviral (ARV) Tender on 14 February 2019, Adcock Ingram is delighted to announce that it has been successful in winning a number of key products within the tender. Adcock Ingram has been awarded a 12% share of the ARV tender, equating to approximately R1.8 billion (excluding VAT) to supply ARV drugs to state-run hospitals, over a period of three years, effective from 1 July 2019.

The Company submitted bids for the triple combination products, Tenofovir/Emtricitabine/Efavirenz (TEE) and Dolutegravir/Lamivudine/Tenofovir (DLT), as well as a number of the dual and monotherapy molecules.

Adcock Ingram’s share of the ARV Tender award over the three years includes 11% (16.8 million packs) of the 147 million packs of DLT requested in the tender, 2.8 million packs of other oral solid dosage products and 2.7 million bottles of oral solutions.

As a member of Proudly South Africa, Adcock Ingram has its roots firmly entrenched in the South African market. We are proud to be a leading South African manufacturer, which has been recognised as a partner of the State in the national fight against HIV and AIDS. The tender award reflects positively on our manufacturing capability, breadth of our product offering and our historical service delivery levels.

Our investment into the oral solid dosage facility situated in Wadeville has increased our ability to manufacture and supply antiretroviral medicines to the public sector through the tender system, and also meet the needs of the private healthcare market.

‘Adcock Ingram is proud to have been chosen as one of the State’s partners in the fight against one of the biggest epidemics in the world. As a responsible South African manufacturer and supplier of ARV’s, our business model is focused firmly within our ethos of Adding Value to Life and in line with our quest to advance affordable healthcare for all South Africans. We look forward to continuing this partnership with government – united in the fight against AIDS’ says Ashley Pearce, Managing Director: Adcock Ingram Prescription Division.

About Adcock Ingram
Adcock Ingram is a leading South African pharmaceutical manufacturer, founded in 1891, and listed on the Johannesburg Stock Exchange. Adcock Ingram manufactures, markets and distributes a wide range of healthcare products. The Company is a leading supplier to both the private and public sectors of the market. As a leading healthcare provider, the Company’s mission is to provide quality products that improve the health and lives of the people in the markets that we serve. www.adcock.com

Media Contact:
Kavitha Kalicharan
Adcock Ingram Healthcare (Pty) Ltd
Tel: + 27 11 635 0189
Mobile: +79 566 9527
Email: kavitha.kalicharan@adcock.com

[BACK TO ARTICLES]